Lipopolysaccharide animal models for Parkinson's disease.
about
Overnutrition Determines LPS Regulation of Mycotoxin Induced Neurotoxicity in Neurodegenerative DiseasesAlkaloids from piper longum protect dopaminergic neurons against inflammation-mediated damage induced by intranigral injection of lipopolysaccharide.Behavioral and monoamine perturbations in adult male mice with chronic inflammation induced by repeated peripheral lipopolysaccharide administration.Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease.Prostaglandin J2: a potential target for halting inflammation-induced neurodegeneration.Differential neuroprotective and anti-inflammatory effects of L-type voltage dependent calcium channel and ryanodine receptor antagonists in the substantia nigra and locus coeruleusSomatostatin prevents lipopolysaccharide-induced neurodegeneration in the rat substantia nigra by inhibiting the activation of microglia.Mitochondrial Impairment in Cerebrovascular Endothelial Cells is Involved in the Correlation between Body Temperature and Stroke Severity.Acute induction of anomalous and amyloidogenic blood clotting by molecular amplification of highly substoichiometric levels of bacterial lipopolysaccharideInflammation in rat pregnancy inhibits spiral artery remodeling leading to fetal growth restriction and features of preeclampsiaMicroglia and neuronal cell death.Inflammation in Parkinson's disease: role of glucocorticoids.Alternative microglial activation is associated with cessation of progressive dopamine neuron loss in mice systemically administered lipopolysaccharide.Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson's Disease.The potential role of neuroinflammation and transcription factors in Parkinson diseaseImplications of Neuroinvasive Bacterial Peptides on Rodents Behaviour and Neurotransmission.Apocyanin, a Microglial NADPH Oxidase Inhibitor Prevents Dopaminergic Neuronal Degeneration in Lipopolysaccharide-Induced Parkinson's Disease Model.Ifngr1 and Stat1 mediated canonical Ifn-γ signaling drives nigrostriatal degeneration.Icariin Reduces Dopaminergic Neuronal Loss and Microglia-Mediated Inflammation in Vivo and in Vitro.Bioconversion of Tyrosine and Tryptophan Derived Biogenic Amines by Neuropathogenic Bacteria.No effects without causes: the Iron Dysregulation and Dormant Microbes hypothesis for chronic, inflammatory diseases.Acute Neuroinflammatory Response in the Substantia Nigra Pars Compacta of Rats after a Local Injection of Lipopolysaccharide.Association Between Peripheral Inflammation and DATSCAN Data of the Striatal Nuclei in Different Motor Subtypes of Parkinson Disease.Neuroimmunological Implications of Subclinical Lipopolysaccharide from EnteritidisDistribution and Neurochemistry of the Porcine Ileocaecal Valve Projecting Sensory Neurons in the Dorsal Root Ganglia and the Influence of Lipopolysaccharide from Different Serotypes of spp. on the Chemical Coding of DRG Neurons in the Cell CulturesProstaglandin D2/J2 signaling pathway in a rat model of neuroinflammation displaying progressive parkinsonian-like pathology: potential novel therapeutic targetsThe Healing Effect of Human Milk Fat Globule-EGF Factor 8 Protein (MFG-E8) in A Rat Model of Parkinson's DiseaseEffect of Chlorogenic Acid Supplementation in MPTP-Intoxicated MouseTargeting the noradrenergic system for anti-inflammatory and neuroprotective effects: implications for Parkinson's diseaseCorrelative Light-Electron Microscopy detects lipopolysaccharide and its association with fibrin fibres in Parkinson's Disease, Alzheimer's Disease and Type 2 Diabetes MellitusP7C3 Inhibits LPS-Induced Microglial Activation to Protect Dopaminergic Neurons Against Inflammatory Factor-Induced Cell Death and
P2860
Q26774272-EF4B1AE8-9CE8-422C-8885-364D690B5244Q30371352-290D9C57-688D-4C66-AE3A-D83B274306E6Q30719160-A434F38B-0276-4398-BABC-401CBDE1B6B8Q34481921-9BF5AA03-A075-4620-8F81-6892F073B06FQ34508284-B98B6322-0178-456A-A041-F15CDE01CA26Q35108124-9906B413-9FD9-4985-8F86-5C4F69B3003DQ35628403-B968E030-8F50-4FDE-88ED-1A21D6E82E10Q36491146-6EC16AE0-B06F-440B-B9BB-3BC78FBB8A62Q37304424-7E3157E8-0291-49DE-86E5-CFAAF481C9BCQ37483133-B9AD3E14-B67E-4816-A558-1A14A2CB6977Q37989248-FF10F17B-5676-4F34-A027-0E8D9D5F8CD4Q38425458-8533E78C-3377-4C26-ACE4-771060F58AADQ38617000-8F3FDCD4-E562-4900-A2FC-EBC408F01906Q38722255-31C0DFBD-FAA1-4162-8427-A5874BAF072EQ39342497-A959055D-2D65-485B-875E-B22AC397DE97Q40050287-B8E9E865-46FD-40CD-A13C-E0C09D3229EAQ46714153-F9E54519-A749-4238-A41E-E747159A4A5FQ47382007-891A075F-3C61-44A8-810A-E02CD015168AQ47836628-D929F20F-E582-41FA-BB96-97319B8A49BBQ50041920-3F9269CD-695B-4F3B-8713-EDADE5FA8E02Q53698735-A40CEA4C-1FE6-40AB-803E-FA242DD161C9Q54981317-7FC12B93-7EB0-4193-BE30-8FB430655E74Q55228224-FED10AF1-8AB6-4519-AF5B-66910D54E29BQ58581338-4FC5E9AE-54A7-40CB-9521-1A22B2CA072BQ58697318-5B5B16FB-281F-43E9-A490-0228008C59B9Q58714026-5E6140E6-FA19-4933-B2C5-1871022681F7Q58779250-003B1C95-89E4-48BE-93BD-7C32F7A059D1Q58799110-8A153FB4-3C47-42A7-8DD4-B3FDC9A6A19AQ58805381-BEB767BB-CC8D-406E-A329-4620E3D51C45Q59127020-7FD9191E-64AE-4F50-8E10-190A11BEDE7EQ59136946-D0C09E37-C687-4141-BF57-BEF840A3A6AC
P2860
Lipopolysaccharide animal models for Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 27 April 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lipopolysaccharide animal models for Parkinson's disease.
@en
Lipopolysaccharide animal models for Parkinson's disease.
@nl
type
label
Lipopolysaccharide animal models for Parkinson's disease.
@en
Lipopolysaccharide animal models for Parkinson's disease.
@nl
prefLabel
Lipopolysaccharide animal models for Parkinson's disease.
@en
Lipopolysaccharide animal models for Parkinson's disease.
@nl
P2860
P356
P1433
P1476
Lipopolysaccharide animal models for Parkinson's disease.
@en
P2093
P2860
P304
P356
10.4061/2011/327089
P50
P577
2011-04-27T00:00:00Z